menthol has been researched along with Amphetamine-Related Disorders in 1 studies
Menthol: A monoterpene cyclohexanol produced from mint oils.
Amphetamine-Related Disorders: Disorders related or resulting from use of amphetamines.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Smoking cessation was assessed via self-report and carbon monoxide levels." | 2.78 | A tale of two stimulants: mentholated cigarettes may play a role in cocaine, but not methamphetamine, dependence. ( Adinoff, B; Brigham, GS; Gardin, JG; Ghitza, U; Lewis, DF; Sonne, SC; Theobald, J; Winhusen, TM, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Winhusen, TM | 1 |
| Adinoff, B | 1 |
| Lewis, DF | 1 |
| Brigham, GS | 1 |
| Gardin, JG | 1 |
| Sonne, SC | 1 |
| Theobald, J | 1 |
| Ghitza, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes[NCT01077024] | Phase 3 | 538 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A combination of daily self-reported smoking data and weekly carbon monoxide levels were used to determine continuous abstinence during post-quit days 15 - 42. (NCT01077024)
Timeframe: Post-quit days 15-42
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 6.7 |
| Substance-treatment as Usual | 0.0 |
point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: Week 10 assessment
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 25.5 |
| Substance-treatment as Usual | 2.2 |
point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: 3- month follow-up visits
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 19.1 |
| Substance-treatment as Usual | 3.0 |
point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: 6 month visit
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 13.1 |
| Substance-treatment as Usual | 3.7 |
At the 3-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back. (NCT01077024)
Timeframe: 3-month follow-up visit
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 74.3 |
| Substance-treatment as Usual | 68.8 |
At the 6-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back. (NCT01077024)
Timeframe: 6 - months follow-up visit
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 69.5 |
| Substance-treatment as Usual | 71.6 |
Stimulant-free week results (no cocaine, methamphetamine and amphetamine use) were obtained by combining the urine drug screens (UDS) and the self-reported Timeline Follow-Back (TLFB). At the group level, this outcome translates into the percentage of weeks in each study arm that are stimulant-free. (NCT01077024)
Timeframe: Week 16
| Intervention | percentage of weeks (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 77.7 |
| Substance-treatment as Usual | 78.0 |
1 trial available for menthol and Amphetamine-Related Disorders
| Article | Year |
|---|---|
A tale of two stimulants: mentholated cigarettes may play a role in cocaine, but not methamphetamine, dependence.
Topics: Adult; Amphetamine-Related Disorders; Behavior, Addictive; Cocaine-Related Disorders; Female; Humans | 2013 |